Skip to Main content Skip to Navigation
Journal articles

Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells

Abstract : A number of nanoparticles has been developed by chemists for biomedical applications to meet imaging and targeting needs. In parallel, adoptive T therapy with chimeric antigen receptor engineered T cells (CART cells) has recently held great promise in B-cell malignancy treatments thanks to the development of anti-CD19 CAR T cells. Indeed, CD19 is a reliable B cell marker and a validated target protein for therapy. In this perspective article, we propose to discuss the advantages, limits and challenges of nanoparticles and CAR T cells, focusing on CD19 targeting objects: anti-CD19 nanoparticles and anti-CD19 CAR T cells, because those genetically-modified cells are the most widely developed in clinical setting. In the first part, we will introduce B cell malignancies and the CD19 surface marker. Then we will present the positioning of nanomedicine in the topic of B cell malignancy, before exposing CAR T technology. Finally, we will discuss the complementary approaches between nanoparticles and CAR T cells.
Complete list of metadatas

Cited literature [4 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01617055
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, October 24, 2017 - 12:02:41 PM
Last modification on : Saturday, July 11, 2020 - 3:16:07 AM
Long-term archiving on: : Thursday, January 25, 2018 - 12:58:11 PM

File

CD19-pour-HAL.pdf
Files produced by the author(s)

Identifiers

Citation

Helene Jakobczyk, Flavien Sciortino, Soizic Chevance, Fabienne Gauffre, Marie-Bérengère Troadec. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells. International Journal of Pharmaceutics, Elsevier, 2017, 532 (2), pp.813-824. ⟨10.1016/j.ijpharm.2017.07.075⟩. ⟨hal-01617055⟩

Share

Metrics

Record views

470

Files downloads

337